
News Topical, Digital Desk : Lupin, a company that does business of medicines worldwide including India, has informed about a big change in the business just before the market closed on Tuesday, 1 July. After this information from the company, Lupin stock managed to close at Rs 1,966.70 per share with a gain of 1.48%. One of the medicines of the company has also received approval from the US FDA. The company has informed that it will separate its consumer healthcare unit LupinLife Consumer Healthcare Ltd. as a wholly-owned subsidiary.
This decision of the company will be effective from July 1, 2025. Giving information about this, the company said that it has been taken strategically in view of the rapidly growing self-care market in India.
Who will be the new CEO
The business was started in the year 2017, which has become a strong over-the-counter (OTC) business till now. The company sells many products in the market under this brand, including Softovac, Beplex Forte, Corcium and Aptivate. Anil Kaushal has been appointed as the Chief Executive Officer (CEO) of the new company. On this decision, Nilesh Gupta, Managing Director of Lupin, said that this strategic decision will further strengthen the high-impact business model. LupinLife Consumer Healthcare is a great example of our consumer based focus. Apart from this, Lupin has received approval from the US FDA for Lotemax Ophthalmic Gel. This medicine is used to reduce swelling after eye surgery.
Lupin: Stock Performance After a day's trading on Tuesday, July 1, 2025, Lupin stock closed at Rs 1,966.70 per share with a gain of 1.48%. The stock of this company with a market capitalization of about Rs 89.76 thousand crore has set a 52-week high of Rs 2,402.90. At the same time, the 52-week low of this stock is Rs 1,598.25. Talking about the action in the stock, only about a quarter percent growth has been seen in the last one month. At the same time, it has slipped 16.84% in 6 months. But, during the last one year, the stock has seen a gain of 21.70%.
--Advertisement--